Article content

The CEO of Leamington cannabis producer Aphria — under siege from short-sellers claiming that backroom deals enriched insiders — said the company will release a report next week addressing every allegation.

Vic Neufeld said Aphria’s response will rebut the barrage of accusations levelled Monday that mostly focused on the company’s recent acquisitions in Latin America.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or Aphria says it will provide line-by-line rebuttal to short seller allegations Back to video

“You will find all of the 20-some allegations, line-by-line, point-by-point with pictures — real pictures, truthful pictures — on what we have called LATAM asset acquisition,” Neufeld told the Star on Friday. “Every point will be very informative and will shed the real light on the story.”

He said that rebuttal will likely be released Wednesday. Aphria announced Thursday it had appointed an independent committee to review the company’s recent acquisition of its Latin American holdings and confirm it was on the level.

What I don’t want to do is waste shareholder money and executive management time on something that could end up with a realization of zero.

Neufeld said Liberty Health Sciences, a company backed by Aphria that was the target of a second round of allegations, will likely release its own response on Monday.

He said the possibility of litigation prevents him from addressing specific details of the allegations until the official response next week.

“I am not hiding,” he said. “We’re just very focused on getting it right in terms of all of the facts — those that have been disclosed and those that we’re going to have to disclose — to make sure that we’re not pre-emptively giving selective disclosure.”

But he said it will be “proven by further forensic legal work” that no insiders were enriched at the detriment of unwitting shareholders.

That was one of many allegations from Quintessential Capital Management and the forensic analysis firm Hindenburg Research, who took aim at Aphria on Monday, calling it a “shell game” and a “black hole.”

Both Quintessential and Hindenburg were reportedly short-selling Aphria stock. A short-seller can profit if a security’s price declines.

They claim Aphria diverted funds into inflated investments held by insiders, and that its recent Latin American transactions are worthless. Hindenburg claimed the official registered office of Aphria’s $145-million Jamaican acquisition “is an abandoned building that was sold off by the bank earlier this year.”